InvestorsHub Logo
Followers 50
Posts 9477
Boards Moderated 2
Alias Born 10/25/2007

Re: None

Friday, 03/14/2025 8:48:55 AM

Friday, March 14, 2025 8:48:55 AM

Post# of 188
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Cash Position: Cash and cash equivalents as of December 31, 2024 were $102.7 million, as compared to $35.4 million as of December 31, 2023. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.

https://www.biospace.com/press-releases/candel-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-highlights
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CADL News